Cancer Type/Condition: Leukemia, acute lymphocytic (ALL), adult
Stage/Subtype: untreated adult acute lymphoblastic leukemia
Country: U.S.A.
Trial Type: Treatment
Trial Status: Active
1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to under 31
Sponsor: NCI
Protocol IDs: COG-AALL0232, NCT00075725, AALL0232
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to under 31
Sponsor: NCI
Protocol IDs: COG-AALL0434, AALL0434, NCT00408005
|
|
3.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ID03-0124, NCT00452439
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP4055-106, NCT00405743
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AT9283/0002, 2006-0177, NCT00522990
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 0 to 55
Sponsor: Other
Protocol IDs: 8717, NCT00673114
|
|
7.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Protocol 2036-01, NCT00827138
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9090-04, NCT00964873
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 265-103, NCT00975767
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: NCI
Protocol IDs: CPMC-IRB-AAAA5571, CPMC-CAMP-016, NCI-G00-1891, NCT00008216
|
|
11.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: Under 75
Sponsor: NCI
Protocol IDs: FHCRC-1898.00, 5788, NCT00089011
|
|
12.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: FHCRC-1938.00, 5887, NCT00105001
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and over
Sponsor: NCI
Protocol IDs: JHOC-J0409, JHOC-04-05-13-01, NCT00133991
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 55
Sponsor: Other
Protocol IDs: 9L-03-1, NCT00184041
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-0478, NCT00390793
|
|
16.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187
|
|
17.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: JHOC-J06114, J06114, 7605, NA_00006989, NCT00462605
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 50
Sponsor: Other
Protocol IDs: 06-254, NCT00476190
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2006-0328, NCT00501826
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 22 to 50
Sponsor: Other
Protocol IDs: 05-DCB, NCT00514579
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 to 39
Sponsor: NCI
Protocol IDs: CALGB-10403, CALGB 10403, ECOG C10403, SWOG C10403, NCT00558519
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: ID02-230, NCT00671658
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 11300A, NCT00683046
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 08-087, NCT00739141
|
|
25.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 50
Sponsor: NCI
Protocol IDs: SWOG-S0805, S0805, NCT00792948
|
